Lifecore initiated by JMP at market outperform

Lifecore Biomedical, Inc. coverage was initiated by JMP Securities analyst Anthony Ostrea at a market outperform rating and $17 price target. The company has exposure to dental implants, the fastest growing segment in the dental space, and also has high visibility on its hyaluronic business. JMP forecasts revenue growth to $78 million and earnings per share of $0.76 by fiscal year 2008. Shares of the Chaska, Minn., maker of biomaterials was up 2 cents, or 0.13%, at $15.28 on volume of 36,404 shares versus the three-month running average of 59,461.5 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.